Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Investments (2016 - 2024)

Seres Therapeutics (MCRB) has disclosed Long-Term Investments for 9 consecutive years, with $1.4 million as the latest value for Q1 2024.

  • Quarterly Long-Term Investments changed 0.0% to $1.4 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Mar 2024, changed 0.0% year-over-year, with the annual reading at $1.4 million for FY2023, 0.0% changed from the prior year.
  • Long-Term Investments hit $1.4 million in Q1 2024 for Seres Therapeutics, roughly flat from $1.4 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $49.8 million in Q4 2020 to a low of $495000.0 in Q4 2021.
  • Historically, Long-Term Investments has averaged $7.8 million across 5 years, with a median of $1.4 million in 2022.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 3458.93% in 2020 and later plummeted 99.01% in 2021.
  • Year by year, Long-Term Investments stood at $49.8 million in 2020, then tumbled by 99.01% to $495000.0 in 2021, then soared by 183.03% to $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024.
  • Business Quant data shows Long-Term Investments for MCRB at $1.4 million in Q1 2024, $1.4 million in Q4 2023, and $1.4 million in Q3 2023.